Portfolio Holdings Detail for ISIN IE00B42YS929
| Stock Name / Fund | iShares MSCI World GBP Hedged UCITS ETF (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares V Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300QETNU1W5JY7Z94 |
| ETF Ticker | IGWD(GBX) LSE |
| ETF Ticker | IGWD.LS(GBX) CXE |
| ETF Ticker | IGWD.L(GBP) LSE |
Holdings detail for NBIX
| Stock Name | Neurocrine Biosciences Inc |
| Ticker | NBIX(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US64125C1099 |
| LEI | 549300FECER0XBN49756 |
Show aggregate NBIX holdings
News associated with NBIX
- Sum Up The Parts: SCHG Could Be Worth $34
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-21 10:23:31
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Maryland State Retirement & Pension System
- Maryland State Retirement & Pension System lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,661 shares of the company’s stock after selling 663 shares during the quarter. Maryland […] - 2025-08-15 05:24:56
- Charles Schwab Investment Management Inc. Purchases 13,216 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Charles Schwab Investment Management Inc. raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 775,773 shares of the company’s stock after acquiring an additional 13,216 shares during the quarter. Charles […] - 2025-08-13 05:10:46
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Blair William & Co. IL
- Blair William & Co. IL cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.7% in the first quarter, Holdings Channel reports. The fund owned 6,214 shares of the company’s stock after selling 242 shares during the period. Blair William & Co. IL’s holdings in Neurocrine Biosciences were worth $687,000 at the […] - 2025-08-11 05:52:52
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Federated Hermes Inc.
- Federated Hermes Inc. trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 72.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,441 shares of the company’s stock after selling 25,402 shares during the quarter. Federated Hermes Inc.’s […] - 2025-08-07 05:22:58
- Natixis Advisors LLC Sells 292 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Natixis Advisors LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.9% in the first quarter, Holdings Channel.com reports. The institutional investor owned 33,312 shares of the company’s stock after selling 292 shares during the period. Natixis Advisors LLC’s holdings in Neurocrine Biosciences were worth $3,684,000 at the end of the […] - 2025-08-07 04:49:07
- Neurocrine (NBIX) Q2 2025 Earnings Call Transcript
- @media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo - 2025-08-05 01:16:10
- Neurocrine (NBIX) Q2 Revenue Jumps 17%
- Key PointsNon-GAAP earnings per share of $1.65 for Q2 2025 vastly exceeded the analyst estimate of $0.96. - 2025-08-01 01:15:16
- 13,202 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by Y Intercept Hong Kong Ltd
- Y Intercept Hong Kong Ltd acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 13,202 shares of the company’s stock, valued at approximately $1,460,000. Other hedge funds and other institutional investors have also recently bought and sold shares of the company. […] - 2025-07-24 06:50:57
- HighPoint Advisor Group LLC Purchases 366 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- HighPoint Advisor Group LLC boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 15.0% during the first quarter, Holdings Channel.com reports. The fund owned 2,812 shares of the company’s stock after acquiring an additional 366 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Neurocrine Biosciences were worth $302,000 […] - 2025-07-24 05:51:14
- Neurocrine Biosciences (NASDAQ:NBIX) Now Covered by Analysts at Truist Financial
- Truist Financial initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research report report published on Monday, Marketbeat reports. The firm issued a buy rating and a $163.00 price target on the stock. NBIX has been the subject of several other reports. Royal Bank Of Canada reaffirmed an “outperform” rating and […] - 2025-07-22 04:28:48
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Trimmed by Cerity Partners LLC
- Cerity Partners LLC decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 20.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,361 shares of the company’s stock after selling 8,376 shares during the quarter. Cerity Partners LLC’s holdings in […] - 2025-07-18 04:55:08
- Ingrid Delaet Sells 457 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Ingrid Delaet sold 457 shares of the business’s stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the completion of the transaction, the insider directly owned 4,730 shares in the […] - 2025-07-14 07:16:47
- Bank of New York Mellon Corp Has $91.65 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Bank of New York Mellon Corp lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 4.8% during the first quarter, HoldingsChannel reports. The fund owned 828,682 shares of the company’s stock after selling 41,608 shares during the quarter. Bank of New York Mellon Corp’s holdings in Neurocrine Biosciences were worth $91,652,000 as […] - 2025-07-11 05:40:57
- Principal Financial Group Inc. Has $27.48 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Principal Financial Group Inc. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 248,420 shares of the company’s stock after selling 4,049 shares during the period. Principal Financial Group Inc. owned 0.25% of Neurocrine Biosciences […] - 2025-07-09 05:51:40
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of “Moderate Buy” by Analysts
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-two brokerages that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and nineteen have given a buy recommendation to the company. The average 12 […] - 2025-07-09 03:09:50
- First Horizon Advisors Inc. Has $43,000 Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- First Horizon Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 55.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 385 shares of the company’s stock after selling 480 shares during the quarter. First Horizon Advisors […] - 2025-07-08 05:49:06
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Jude Onyia Sells 20,362 Shares
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Jude Onyia sold 20,362 shares of the company’s stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $130.13, for a total value of $2,649,707.06. Following the completion of the sale, the insider owned 18,289 shares of the company’s […] - 2025-07-08 05:06:50
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by KBC Group NV
- KBC Group NV lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.5% in the 1st quarter, Holdings Channel reports. The fund owned 13,835 shares of the company’s stock after selling 495 shares during the period. KBC Group NV’s holdings in Neurocrine Biosciences were worth $1,530,000 as of its most recent filing […] - 2025-07-04 06:58:45
- New York State Teachers Retirement System Lowers Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- New York State Teachers Retirement System lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.9% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 108,481 shares of the company’s stock after selling 2,055 shares during the quarter. New York State Teachers Retirement System’s holdings in Neurocrine Biosciences were worth $11,998,000 […] - 2025-07-04 06:14:58
- Amalgamated Bank Has $5.28 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Amalgamated Bank lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,719 shares of the company’s stock after selling 1,895 shares during the quarter. Amalgamated Bank’s holdings in Neurocrine Biosciences were […] - 2025-07-03 06:14:49
- Sumitomo Mitsui Trust Group Inc. Sells 1,399 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Sumitomo Mitsui Trust Group Inc. reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 231,458 shares of the company’s stock after selling 1,399 shares during the quarter. Sumitomo Mitsui Trust […] - 2025-07-03 05:35:01
- Golden State Wealth Management LLC Grows Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Golden State Wealth Management LLC increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 116.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 397 shares of the company’s stock after purchasing an additional 214 shares during the quarter. […] - 2025-07-02 05:01:01
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Oppenheimer & Co. Inc.
- Oppenheimer & Co. Inc. raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.4% in the 1st quarter, HoldingsChannel.com reports. The fund owned 19,388 shares of the company’s stock after buying an additional 447 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Neurocrine Biosciences were worth $2,144,000 as […] - 2025-06-27 05:10:49
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Retirement Systems of Alabama
- Retirement Systems of Alabama cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.4% in the 1st quarter, Holdings Channel reports. The firm owned 121,352 shares of the company’s stock after selling 1,755 shares during the period. Retirement Systems of Alabama’s holdings in Neurocrine Biosciences were worth $13,422,000 at the […] - 2025-06-23 05:04:51
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by QRG Capital Management Inc.
- QRG Capital Management Inc. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,062 shares of the company’s stock after buying an additional 1,330 shares […] - 2025-06-20 06:54:59
- Sowell Financial Services LLC Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Sowell Financial Services LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,786 shares of the company’s stock, valued at approximately $529,000. Other institutional investors and hedge funds […] - 2025-06-20 05:29:06
- Trust Point Inc. Sells 660 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Trust Point Inc. decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 26.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,823 shares of the company’s stock after selling 660 shares during the period. Trust Point Inc.’s holdings in […] - 2025-06-19 05:35:02
- XBI, EXAS, NBIX, NTRA: ETF Outflow Alert
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $443.9 million dollar outflow -- that's a 8.8% decrease week over week - 2025-06-17 11:54:37
- Merit Financial Group LLC Acquires 345 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Merit Financial Group LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 9.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,153 shares of the company’s stock after purchasing an additional 345 shares during the quarter. Merit Financial Group […] - 2025-06-11 05:00:51
iShares MSCI World GBP Hedged UCITS ETF (Acc) NBIX holdings
| Date | Number of NBIX Shares Held | Base Market Value of NBIX Shares | Local Market Value of NBIX Shares | Change in NBIX Shares Held | Change in NBIX Base Value | Current Price per NBIX Share Held | Previous Price per NBIX Share Held |
|---|
| 2025-11-27 (Thursday) | 683 | USD 78,135 | USD 78,135 | 0 | USD -133 | USD 114.4 | USD 114.594 |
| 2025-11-26 (Wednesday) | 683 | USD 78,268 | USD 78,268 | 0 | USD 3,870 | USD 114.594 | USD 108.928 |
| 2025-11-25 (Tuesday) | 683 | USD 74,398 | USD 74,398 | 0 | USD 740 | USD 108.928 | USD 107.845 |
| 2025-11-24 (Monday) | 683 | USD 73,658 | USD 73,658 | 0 | USD 1,167 | USD 107.845 | USD 106.136 |
| 2025-11-20 (Thursday) | 683 | USD 72,491 | USD 72,491 | 0 | USD 452 | USD 106.136 | USD 105.474 |
| 2025-11-18 (Tuesday) | 683 | USD 72,039 | USD 72,039 | 0 | USD -2,375 | USD 105.474 | USD 108.952 |
| 2025-11-17 (Monday) | 683 | USD 74,414 | USD 74,414 | 0 | USD -195 | USD 108.952 | USD 109.237 |
| 2025-11-13 (Thursday) | 683 | USD 74,609 | USD 74,609 | 0 | USD -1,771 | USD 109.237 | USD 111.83 |
| 2025-11-12 (Wednesday) | 683 | USD 76,380 | USD 76,380 | 0 | USD 33 | USD 111.83 | USD 111.782 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of NBIX by Blackrock for IE00B42YS929
Show aggregate share trades of NBIX| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-03 | BUY | 23 | 137.030 | 137.800 | 137.723 | USD 3,168 | 93.59 |
| 2025-08-21 | BUY | 23 | 135.280 | 135.630 | 135.595 | USD 3,119 | 92.81 |
| 2025-07-02 | BUY | 23 | 129.400 | 130.420 | 130.318 | USD 2,997 | 92.11 |
| 2024-12-30 | SELL | -23 | 137.060 | 138.650 | 138.491 | USD -3,185 | 96.13 Loss of -974 on sale |
| 2024-11-18 | BUY | 23 | 117.620 | 118.320 | 118.250 | USD 2,720 | 92.81 |
| 2024-10-30 | SELL | -23 | 124.330 | 131.260 | 130.567 | USD -3,003 | 89.41 Loss of -947 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of NBIX
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 138,304 | 0 | 280,714 | 49.3% |
| 2025-09-18 | 207,776 | 44,506 | 326,194 | 63.7% |
| 2025-09-17 | 106,323 | 343 | 194,597 | 54.6% |
| 2025-09-16 | 97,811 | 19,146 | 256,980 | 38.1% |
| 2025-09-15 | 73,363 | 0 | 197,457 | 37.2% |
| 2025-09-12 | 71,817 | 1,305 | 193,968 | 37.0% |
| 2025-09-11 | 87,204 | 0 | 250,369 | 34.8% |
| 2025-09-10 | 117,099 | 0 | 288,605 | 40.6% |
| 2025-09-09 | 123,379 | 1,879 | 226,941 | 54.4% |
| 2025-09-08 | 213,669 | 1,667 | 350,787 | 60.9% |
| 2025-09-05 | 269,882 | 8,988 | 447,930 | 60.3% |
| 2025-09-04 | 193,322 | 481 | 275,129 | 70.3% |
| 2025-09-03 | 210,597 | 108 | 556,905 | 37.8% |
| 2025-09-02 | 183,319 | 15,512 | 318,150 | 57.6% |
| 2025-08-29 | 101,061 | 7,590 | 154,079 | 65.6% |
| 2025-08-28 | 127,383 | 487 | 193,561 | 65.8% |
| 2025-08-27 | 137,454 | 1,818 | 217,033 | 63.3% |
| 2025-08-26 | 170,022 | 3,558 | 291,096 | 58.4% |
| 2025-08-25 | 124,153 | 3,639 | 195,476 | 63.5% |
| 2025-08-22 | 126,629 | 10,885 | 196,288 | 64.5% |
| 2025-08-21 | 119,245 | 1,265 | 200,990 | 59.3% |
| 2025-08-20 | 135,138 | 4,637 | 230,010 | 58.8% |
| 2025-08-19 | 186,010 | 535 | 287,330 | 64.7% |
| 2025-08-18 | 162,038 | 7,351 | 232,609 | 69.7% |
| 2025-08-15 | 140,024 | 100 | 220,199 | 63.6% |
| 2025-08-14 | 290,907 | 253 | 363,139 | 80.1% |
| 2025-08-13 | 356,404 | 8,730 | 466,191 | 76.5% |
| 2025-08-12 | 303,975 | 4,067 | 434,641 | 69.9% |
| 2025-08-11 | 279,191 | 5,617 | 413,027 | 67.6% |
| 2025-08-08 | 338,385 | 0 | 490,220 | 69.0% |
| 2025-08-07 | 341,719 | 2 | 486,060 | 70.3% |
| 2025-08-06 | 162,494 | 52 | 290,741 | 55.9% |
| 2025-08-05 | 127,812 | 122 | 285,401 | 44.8% |
| 2025-08-04 | 184,650 | 798 | 554,601 | 33.3% |
| 2025-08-01 | 384,652 | 274 | 613,137 | 62.7% |
| 2025-07-31 | 795,027 | 2 | 1,403,519 | 56.6% |
| 2025-07-30 | 277,359 | 199 | 566,942 | 48.9% |
| 2025-07-29 | 235,483 | 1,232 | 479,504 | 49.1% |
| 2025-07-28 | 128,796 | 1,272 | 304,763 | 42.3% |
| 2025-07-25 | 164,959 | 0 | 533,682 | 30.9% |
| 2025-07-24 | 143,137 | 442 | 360,991 | 39.7% |
| 2025-07-23 | 127,087 | 250 | 336,567 | 37.8% |
| 2025-07-22 | 110,378 | 700 | 199,614 | 55.3% |
| 2025-07-21 | 94,768 | 91 | 171,481 | 55.3% |
| 2025-07-18 | 136,185 | 216 | 238,836 | 57.0% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.